
OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma
OS Therapies has submitted an application to the FDA requesting regenerative medicine advanced therapy (RMAT) designation for OST-HER2 (OST31-164). OST-HER2 is an investigational immunotherapy being evaluated for the prevention of metastatic recurrence in …